Diabetes Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight

October 21 19:22 2022
Diabetes Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight
Diabetes Pipeline
Diabetes pipeline constitutes 200+ key companies continuously working towards developing 200+ Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyses DelveInsight.

Diabetes Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetes Market.

The Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

To know more in detail about the Diabetes Report and analysis, click here: Diabetes Pipeline Insight

 

Some of the key takeaways from the Diabetes Pipeline

  • Companies across the globe are diligently working toward developing novel Diabetes treatment therapies with a considerable amount of success over the years. Diabetes Key players such as – Nano Precision Medical, Enthera, Pfizer, Scohia Pharma, Carmot Therapeutics, ImCyse, REMD Biotherapeutics, Genexine, Eli Lilly and Company, Dompe Farmaceutici, Oramed, and others, are developing therapies for the Diabetes treatment
  • Diabetes Emerging therapies such as – NPM-119, Ent001, PF 07081532, SCO-094, CT-388, IMCY 0098, Volagidemab, GX G6, LY3209590, Ladarixin, ORMD-0801, and others are expected to have a significant impact on the Diabetes market in the coming years.
  • In December 2020, Dompé Farmaceutici S.p.A initiated a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy – Safety of 400 mg Twice a Day Oral Ladarixin in Pts With New-onset Type 1 Diabetes and Low Residual β-cell Function at Baseline (GLADIATOR STUDY)
  • In March 2021, Oramed initiated a trial titled, “A Double-Blind, Placebo-controlled, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in T2DM Subjects With Inadequate Glycemic Control on Diet Control Only or on Diet Control and Metformin Monotherapy”

 

Diabetes Overview:

Diabetes is a disease that occurs when the blood glucose, also called blood sugar, is too high.

There are a few different types of diabetes: Type 1 diabetes is an autoimmune disease: The immune system attacks and destroys cells in the pancreas, where insulin is made. It’s unclear what causes this attack. About 10 percent of people with diabetes have this type.

Type 2 diabetes occurs when your body becomes resistant to insulin, and sugar builds up in your blood. Prediabetes occurs when your blood sugar is higher than normal, but it’s not high enough for a diagnosis of type 2 diabetes. Gestational diabetes is high blood sugar during pregnancy. Insulin-blocking hormones produced by the placenta cause this type of diabetes.

 

 

Diabetes Pipeline Therapeutics Assessment

  • Diabetes Assessment by Product Type
  • Diabetes By Stage and Product Type
  • Diabetes Assessment by Route of Administration
  • Diabetes By Stage and Route of Administration
  • Diabetes Assessment by Molecule Type
  • Diabetes by Stage and Molecule Type

 

Get a Free Sample PDF Report to know more about Diabetes Pipeline Assessment- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight

 

DelveInsight’s Diabetes Report covers around 200+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging Diabetes Drugs Under Different Phases of Clinical Development Include:

  • NPM-119: Nano Precision Medical
  • Ent001: Enthera
  • PF 07081532: Pfizer
  • SCO-094: Scohia Pharma
  • CT-388: Carmot Therapeutics
  • IMCY 0098: ImCyse
  • Volagidemab: REMD Biotherapeutics
  • GX G6: Genexine
  • LY3209590: Eli Lilly and Company
  • Ladarixin: Dompe Farmaceutici
  • ORMD-0801: Oramed

 

Diabetes Pipeline Analysis:

The Diabetes pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the Diabetes treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment.
  • Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Diabetes product details are provided in the report. Download the Diabetes pipeline report to learn more about the emerging Diabetes therapies at: Diabetes clinical trial advancements

 

Diabetes Pipeline Market Drivers

  • Increasing prevalence of diabetes worldwide
  • Need for effective treatment with low side effects
  • Growing investment in drug development to manage diabetes

 

Diabetes Pipeline Market Barriers

  • Patent Expiration of Drugs

 

Scope of Diabetes Pipeline Drug Insight

  • Coverage: Global
  • Key Diabetes Companies: , and others
  • Key Diabetes Therapies: NPM-119, Ent001, PF 07081532, SCO-094, CT-388, IMCY 0098, Volagidemab, GX G6, LY3209590, Ladarixin, ORMD-0801, and others
  • Diabetes Therapeutic Assessment: Diabetes current marketed and Diabetes emerging therapies
  • Diabetes Market Dynamics: Diabetes market drivers and Diabetes market barriers

 

Request for Sample PDF Report for Diabetes Pipeline Assessment and clinical trials- Recent Developments in the Diabetes Clinical Landscape

 

Table of Contents

Introduction

Executive Summary

Diabetes: Overview

• Causes

• Mechanism of Action

• Signs and Symptoms

• Diagnosis

• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type

• Assessment by Stage and Product Type

• Assessment by Route of Administration

• Assessment by Stage and Route of Administration

• Assessment by Molecule Type

• Assessment by Stage and Molecule Type

Diabetes – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• Diabetes companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Diabetes Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis

• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Enavogliflozin: Daewoong

• Product Description

• Research and Development

• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Golimumab: Janssen Biotech

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase II/I)

• Comparative Analysis

IMCY-0098: ImCyse

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

• Comparative Analysis

ENT-001: Enthera

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Diabetes Key Companies

Diabetes Key Products

Diabetes- Unmet Needs

Diabetes- Market Drivers and Barriers

Diabetes- Future Perspectives and Conclusion

Diabetes Analyst Views

Diabetes Key Companies

Appendix

 

Download Sample PDF Report to know more about Diabetes drugs and therapies by clicking here: – Diabetes Treatment and Medication

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/diabetes-pipeline-insight

  Categories: